In recent years, medications that indirectly control secretion of insulin (e.g. glucagon-like peptide 1 receptor agonist [GLP-1r]) have gained interest as a potential therapeutic intervention for AUD, prompting our laboratory to investigate insulin/IGF-1 systems for its potential role in alcohol-related memory disruptions [67–69]. This evidence concerns the gene INS and alcohol drinking.